Floatz logo

e6 tcr

Cervical Cancer

National Cancer Institute (NCI)Cell therapyPhase 1/2Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
65/ 100

Competitive context

160 Active assets in the Cervical Cancer cohort.

Asset / SponsorPhaseRating
Vinorelbine
UNICANCER
Phase 2BBB
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
Indocyanine Green
Istanbul University
Phase 4BB
TECHNETIUM-99
Institut de Cancérologie de Lorraine
Phase 3B
Cyclophosphamide
Merck Sharp & Dohme LLC
Phase 3B

View all 50 →

Same molecule, other indications

e6 tcr is also rated in:

oropharyngeal carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
vaginal cancerDormant
CCC
Indicative ·
50 / 100
View asset →
penile cancerDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →